News|Articles|November 16, 2026

FDA Approves Gefurulimab as First Once-Weekly, Self-Administered C5 Inhibitor for gMG

Listen
0:00 / 0:00

Key Takeaways

  • FDA approval establishes once-weekly, at-home autoinjector administration for C5 inhibition in AChR-positive gMG, potentially reducing infusion-center dependence and reshaping adherence and access dynamics.
  • Dual-binding nanobody design combines C5 blockade with albumin binding to extend half-life, using a single loading dose then weight-based weekly maintenance dosing.
SHOW MORE

Adults with AChR antibody–positive generalized myasthenia gravis now have a C5 inhibitor they can inject themselves at home once a week.

The FDA has approved gefurulimab (Klygefa; Alexion, AstraZeneca) for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. The company says gefurulimab is the first treatment to pair C5 complement inhibition with once-weekly self-administration by autoinjector.1

Understanding gMG

Generalized myasthenia gravis is a rare autoimmune disorder that disrupts nerve-to-muscle communication, causing weakness and fatigue that come and go. Early symptoms may include slurred speech, double vision, drooping eyelids, and balance problems. Advanced disease can impair swallowing and breathing and, in some cases, lead to respiratory failure.1

In the US, an estimated 98,500 individuals are diagnosed with gMG, and approximately 85% of individuals with the condition are AChR antibody positive.1

What Is Gefurulimab?

Gefurulimab is a dual-binding nanobody that binds to and blocks C5, which prevents C5 from being split into the proinflammatory fragments C5a and C5b. The agent also binds to serum albumin, which extends its half-life and allows once-weekly dosing.1,2

Treatment starts with a single weight-based loading dose on day 1, followed by weight-based maintenance doses starting on day 8 and continuing weekly. In the PREVAIL trial, loading doses were 600 mg or 900 mg and maintenance doses were 300 mg or 600 mg, depending on body weight.1

PREVAIL Trial Results

The approval is based on data from PREVAIL (NCT05556096), a global, randomized, double-blind, placebo-controlled phase 3 trial conducted at 113 sites across 20 countries. Investigators randomly assigned 260 adults with AChR antibody–positive gMG and Myasthenia Gravis Foundation of America class II to IV disease to receive gefurulimab (n = 131) or placebo (n = 129) for 26 weeks. Patients who completed the randomized period could enroll in an ongoing open-label extension.1

The trial met its primary end point. At week 26, Myasthenia Gravis Activities of Daily Living (MG-ADL) total scores decreased by 4.2 points with gefurulimab vs 2.6 points with placebo (treatment difference, −1.6; 95% CI, −2.4 to −0.8; P < .001). AstraZeneca reported that improvements began as early as week 1 and were sustained through 1 year.1,3

Gefurulimab also met its key secondary end point. Quantitative Myasthenia Gravis (QMG) scores fell by 4.5 points with gefurulimab vs 2.4 points with placebo (treatment difference, −2.1; 95% CI, −3.1 to −1.1; P < .001). In addition, 46.8% of patients in the gefurulimab group achieved a QMG reduction of at least 5 points, compared with 28.0% in the placebo group. The results were published in JAMA Neurology.3

Safety Profile

Gefurulimab was generally well tolerated, and its safety profile was consistent with that of the C5 inhibitors eculizumab and ravulizumab in gMG. Adverse events occurred in 75.6% of patients receiving gefurulimab and 80.6% of those receiving placebo. Serious adverse events occurred in 9.2% and 11.6%, respectively. None of the serious adverse events in the gefurulimab group were considered treatment-related, and no meningococcal infections were reported.1

The most common adverse events with gefurulimab were injection site reactions (12%), back pain (8%), and vomiting (5%). No patients stopped taking part in the trial because of an injection site reaction.1

Implications for Pharmacists

Pharmacists will have a central role in supporting patients who inject themselves at home. This includes training on autoinjector technique, rotating injection sites, and keeping to the weekly schedule. Because patients give the drug themselves, it may reduce the need for regular infusion center visits.

Complement inhibition also means patients need counseling about infection risk. According to the CDC, individuals receiving complement inhibitors have a risk of meningococcal disease up to 2000 times greater than otherwise healthy individuals. The prescribing information for currently approved complement inhibitors carries a boxed warning for this risk. The CDC recommends both MenACWY and MenB vaccines for patients on complement inhibitor therapy. It notes that vaccination gives incomplete protection and advises clinicians to stay alert for meningococcal symptoms, even when they first appear mild. Pharmacists should check the full US prescribing information for gefurulimab for its specific vaccination requirements and warnings.4

Looking Ahead

Gefurulimab adds a once-weekly option that patients give themselves to a class of C5 inhibitors that has mostly relied on intravenous infusion. Long-term data from the PREVAIL open-label extension are expected to show more about how long its benefit lasts and its safety over time.1

REFERENCES
1. Klygefa (gefurulimab) approved in the US as the first and only self-administered, once-weekly C5 inhibitor for adults with generalised myasthenia gravis. News release. AstraZeneca. November 16, 2026. Accessed November 16, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/klygefa-gefurulimab-approved-in-the-US.html
2. Klygefa. European Medicines Agency. September 17, 2026. Accessed November 16, 2026. https://www.ema.europa.eu/en/medicines/human/EPAR/klygefa
3. Gwathmey KG, Saccà F, Howard JF Jr, et al; PREVAIL Trial Investigators. Gefurulimab in AChR antibody–positive generalized myasthenia gravis: the PREVAIL phase 3 randomized clinical trial. JAMA Neurol. 2026;83(9):841-850. doi:10.1001/jamaneurol.2026.2333
4. Clinical Guidance for Managing Meningococcal Disease Risk in Patients Receiving Complement Inhibitor Therapy. CDC. News release. March 6, 2026. Accessed November 16, 2026. https://www.cdc.gov/meningococcal/hcp/clinical-guidance/complement-inhibitor.html

Related to this article